Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Harvard Bioscience stock | $4.1

Own Harvard Bioscience stock in just a few minutes.

Fact checked

Harvard Bioscience, Inc is a medical instruments & supplies business based in the US. Harvard Bioscience shares (HBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Harvard Bioscience employs 505 staff and has a trailing 12-month revenue of around USD$102.1 million.

How to buy shares in Harvard Bioscience

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Harvard Bioscience. Find the stock by name or ticker symbol: HBIO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Harvard Bioscience reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.1, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Harvard Bioscience, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Harvard Bioscience. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Harvard Bioscience share price

Use our graph to track the performance of HBIO stocks over time.

Harvard Bioscience shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$4.1
52-week rangeUSD$1.39 - USD$4.58
50-day moving average USD$4.0294
200-day moving average USD$3.4618
Wall St. target priceUSD$5.5
PE ratio 147.5
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.1239

Buy Harvard Bioscience shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Harvard Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Harvard Bioscience price performance over time

Historical closes compared with the close of $4.1 from 2020-12-09

1 week (2021-01-07) -6.39%
1 month (2020-12-17) -2.38%
3 months (2020-10-16) 24.62%
6 months (2020-07-16) 19.53%
1 year (2020-01-16) 26.93%
2 years (2019-01-16) 19.53%
3 years (2018-01-16) 3.80%
5 years (2016-01-15) 50.74%

Is Harvard Bioscience under- or over-valued?

Valuing Harvard Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harvard Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Harvard Bioscience's P/E ratio

Harvard Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 148x. In other words, Harvard Bioscience shares trade at around 148x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Harvard Bioscience's PEG ratio

Harvard Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.89. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Harvard Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Harvard Bioscience's EBITDA

Harvard Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$8.5 million.

The EBITDA is a measure of a Harvard Bioscience's overall financial performance and is widely used to measure a its profitability.

Harvard Bioscience financials

Revenue TTM USD$102.1 million
Operating margin TTM 0.82%
Gross profit TTM USD$64.6 million
Return on assets TTM 0.33%
Return on equity TTM -8.62%
Profit margin -6.51%
Book value $1.98
Market capitalisation USD$159 million

TTM: trailing 12 months

Shorting Harvard Bioscience shares

There are currently 584,383 Harvard Bioscience shares held short by investors – that's known as Harvard Bioscience's "short interest". This figure is 7.7% down from 632,869 last month.

There are a few different ways that this level of interest in shorting Harvard Bioscience shares can be evaluated.

Harvard Bioscience's "short interest ratio" (SIR)

Harvard Bioscience's "short interest ratio" (SIR) is the quantity of Harvard Bioscience shares currently shorted divided by the average quantity of Harvard Bioscience shares traded daily (recently around 110469.37618147). Harvard Bioscience's SIR currently stands at 5.29. In other words for every 100,000 Harvard Bioscience shares traded daily on the market, roughly 5290 shares are currently held short.

However Harvard Bioscience's short interest can also be evaluated against the total number of Harvard Bioscience shares, or, against the total number of tradable Harvard Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Harvard Bioscience's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Harvard Bioscience shares in existence, roughly 20 shares are currently held short) or 0.0154% of the tradable shares (for every 100,000 tradable Harvard Bioscience shares, roughly 15 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Harvard Bioscience.

Find out more about how you can short Harvard Bioscience stock.

Harvard Bioscience share dividends

We're not expecting Harvard Bioscience to pay a dividend over the next 12 months.

Have Harvard Bioscience's shares ever split?

Harvard Bioscience's shares were split on a 1319:1000 basis on 4 November 2013. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1319 shares. This wouldn't directly have changed the overall worth of your Harvard Bioscience shares – just the quantity. However, indirectly, the new 24.2% lower share price could have impacted the market appetite for Harvard Bioscience shares which in turn could have impacted Harvard Bioscience's share price.

Harvard Bioscience share price volatility

Over the last 12 months, Harvard Bioscience's shares have ranged in value from as little as $1.39 up to $4.58. A popular way to gauge a stock's volatility is its "beta".

HBIO.US volatility(beta: 1.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harvard Bioscience's is 1.6945. This would suggest that Harvard Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Harvard Bioscience overview

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems for use with custom amplifier configurations, vivo-systems solution for in vivo recordings with microelectrode arrays, and vitro-systems for extracellular recordings from microelectrode arrays in vitro; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site